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The eﬀects of montelukast against methotrexate-induced liver damage were investigated. 35 Wistar albino female rats were
divided into 5 groups as follows: group I: control; group II: montelukast (ML); group III: methotrexate (Mtx); group
IV: montelukast treatment after methotrexate application (Mtx+ML); group V: montelukast treatment before methotrexate
application (ML+Mtx). At the end of the experiment, the liver tissues of rats were removed. Malondialdehyde (MDA),
myeloperoxidase (MPO), and reduced glutathione levels were determined from liver tissues. In addition, the liver tissues were
examined histologically. MDA and MPO levels of Mtx group were signiﬁcantly increased when compared to control group.
In Mtx+ML group, these parameters were decreased as compared to Mtx group. Mtx injection exhibited major histological
alterationssuchaseosinophilicstainingandswellingofhepatocytes.Theglycogenstorageinhepatocyteswasobservedasdecreased
by periodic acid schiﬀ staining in Mtx group as compared to controls. ML treatment did not completely ameliorate the lesions and
milder degenerative alterations as loss of the glycogen content was still present. It was showed that montelukast treatment after
methotrexate application could reduce methotrexate-induced experimental liver damage.
1.Introduction
Methotrexate (Mtx), a structural analogue of folic acid,
is widely used as a chemotherapeutic agent for cancer
treatment and for autoimmun diseases [1–3]. With the
widespread use of Mtx, hepatotoxicity is the most important
potential major side eﬀect [4, 5]. It has been reported that
liver damage may occur as well in particular high doses or
following chronic administration of Mtx [6, 7].
Leukotrienes (LTs) are synthesized from membrane
phospholipids in response to cell activation. Cysteinyl-
leukotrienes (CysLTs) are produced from arachidonic acid
through 5-lipoxygenase (5-LO) pathway and act on the
CysLT1 and CysLT2 receptors [8]. In fact, several pathways
are involved in production of reactive oxygen species (ROS),
it has been reported that bioactive metabolites of LTs have
a pivotal role in oxidative stress [9]. In another study,
Beytur et al. [10] reported that the selective reversible
CysLT1 receptor antagonist, montelukast (ML) (MK-0476),
has signiﬁcant antioxidant properties against CP-induced
testicular damage. Previously, we have shown that ML
treatment after Mtx application could reduce Mtx-induced
renal damage [11]. Also, the protective eﬀects of ML have
previously been addressed in other models of cell damage
induced by several drugs [12]. The beneﬁcial eﬀects of ML
in various experimental models of inﬂammation have also
been reported [13, 14].
To our knowledge, there is no report regarding the
protective and therapeutic eﬀects of ML against Mtx-
induced acute liver toxicity. Therefore, the current study was
designed to explore the therapeutic and protective eﬀects of
montelukast against Mtx-induced acute liver damage in rats.2 The Scientiﬁc World Journal
Table 1: The levels of biochemical parameters of all groups.
Parameters Control ML Mtx Mtx + ML ML + Mtx
MDA (nmol/g tissue) 937.5 ±71.03 872.3 ±120.3 1669.9 ±129.7a 443.1 ±32.7b,c 1500 ±80.9
GSH (nmol/g tissue) 1937 ±193.7 2116.3 ±189.1 2185.9 ±321.6 1847.0 ±111.1 1621 ±219.6
M P O( U / gp r o t e i n ) 5 8 .3 ±7.97 0 .07 ±11.7 201.9 ±15.5a 80.7 ±10.7b 154.9 ±29.8
aP<0.05, when compared to the control and ML groups.
bP<0.05, when compared to the Mtx group.
cP<0.05, when compared to the other groups.
2. Methods
2.1. Animals. 35 Wistar albino female rats were housed in
an air-conditioned room with 12-h light and dark cycles,
where the temperature (22 ± 2◦C) and relative humidity
(65–70%) were kept constant. All experimental protocols
were approved by the Inonu University, School of Medicine
Animal Care and Use Committee, Malatya, Turkey.
2.2. Experimental Protocol. The rats were divided into 5
groups as follows: group I: control; group II (ML): control
+ montelukast (Notta tb 10mg, Sanovel, Turkey, 10mg/kg
daily for 10 days p.o.); group III (Mtx): methotrexate
(Methotrexate 50mg, Koc ¸ak Farma, Turkey, single dose
20mg/kg i.p.); group IV (Mtx + ML): methotrexate (single
dose 20mg/kg i.p.) + montelukast (10mg/kg daily for 10
days p.o., after 3 days methotrexate injection); group V
(ML + Mtx): montelukast (10mg/kg daily for 10 days
p.o.) + methotrexate (single dose 20mg/kg i.p, after the
last dose of montelukast). At 24h after the last injection,
rats in all groups were killed and the liver tissues of rats
were collected for further analyses. Part of the liver tissue
specimen was placed in formaldehyde solution for routine
histopathological examination by light microscopy. The
other part was placed in liquid nitrogen and stored at −70◦C
untilassayformalondialdehyde(MDA),reducedglutathione
(GSH), and myeloperoxidase (MPO).
2.3. Biochemical Analysis. The liver tissues were individually
homogenized in ice-cold 0.1M Tris-HCl buﬀer (pH 7.5)
with a homogenizer (IKA Ultra Turrax T 25 basic, IKA
Labotechnik,Staufen,Germany)at16000rpmfor3min.The
homogenates were used to measure the levels of MDA, GSH,
and MPO. All procedures were performed at 4◦C.
MDA levels were assayed spectrophotometrically at 535
and 520nm according to the method of Uchiyama and
Mihara [15]. The results are expressed as nanomoles per
gram wet tissue.
GSH levels were measured using the method of Elman
[16]. GSH is reacted with 5,5-dithiobis-2-nitrobenzoic acid
resulting in the formation of a product which has a
maximal absorbance at 410nm. The results are expressed as
nanomoles per g wet tissue.
Determination of MPO activity was carried out spec-
trophotometrically (T60U Spectrometer, PG Instruments
Limited, AlmaPark, Wibtoft, Leicestershire, UK) using 4-
aminoantipyrine/phenol that is a substrate for MPO-
mediated oxidation by H2O2. The absorbance was read at
510nm and the data were given as U/g protein [17].
2.4. Histological Assessment. Liver tissue was ﬁxed in 10%
formalin and was embedded in paraﬃn. Tissue sections were
c u ta t5 μm, mounted on slides, stained with hematoxyli-
neosin (H-E) for general liver structure and periodic acid
schiﬀ (PAS) to demonstrate the glycogen deposition in hepa-
tocytes.ThesectionswereexaminedbyaLeicaDFC280light
microscope by a histolog unaware of the status of animals.
The liver damage severity was semiquantitatively assessed as
follows; hepatocytes with eosinophilic cytoplasm, hydropic
degeneration (cytoplasmic vacuolization and swelling of
hepatocyte), and loss of the glycogen deposition in hepato-
cytes.Microscopicdamagewasidentiﬁedasabsent(0),slight
(1), moderate (2), and severe (3), for each criterion.
2.5. Statistical Analysis. The results were compared with
Kruskal-Wallis variance analysis. Where diﬀerences among
the groups were detected, group means were compared
using the Mann-Whitney U test. Values of P<0.05
were considered signiﬁcant. All results were expressed as
means± standard deviation (SD).
3. Results
3.1. Biochemical Results. Table 1 summarizes the data ob-
tained on the eﬀects of Mtx and treatment of montelukast
on tissue MDA, MPO, and GSH levels. In brief, methotrexate
treatment caused an elevation of MDA and MPO produc-
tions when compared to the control group (P<0.05).
Montelukast application after methotrexate injection (Mtx +
ML) reduced these parameters signiﬁcantly, whereas treat-
ment of montelukast before methotrexate injection (ML +
Mtx) could not show any beneﬁcial eﬀects on MDA and
MPO levels. When the GSH levels increased in Mtx group,
decreased in Mtx + ML and ML + Mtx groups. But these
changes are not signiﬁcantly.
3.2. Light Microscopic Evaluations. The control group and
ML group showed a normal appearance of the liver cells as
shown in Figures 1(a) and 1(b). In the Mtx group, major his-
tologicalalterationswereobservedsuchaseosinophilicstain-
ing (Figure 2(a)) and swelling of hepatocytes (Figure 2(b)).
Eosinophilic-stained hepatocytes were scattered randomly
among the areas with normal morphology. The glyco-
gen storage in hepatocytes was observed as decreased by
PAS staining in the Mtx group as compared to controls.
(Figure 2(c)). ML treatment did not completely ameliorate
these lesions and milder degenerative alterations as loss of
the glycogen content was still present (Figures 3(a) and














Figure 2: (a) Hepatocytes with eosinophilic cytoplasm (arrows) are observed in Mtx group. (b) Cellular swelling in hepatocytes (arrows) is
noticed in Mtx group. (c) Marked reduction in glycogen content in Mtx group. X66.
Mtx + ML group (Figure 3(c)), eosinophilic-stained hep-
atocytes in ML + Mtx group (Figure 3(d))w e r ee v i d e n t ;
however, histopathological changes were not as extensive as
intheMtxgroup.TreatmentwithMLafterMtxinjectionand
treatment with ML before Mtx injection were similar in term
of microscopic damage.
Microscopic damage score for each group was deter-
mined and results were given in Table 2.
4. Discussion
The using of anticancer drugs is limited due to their acute
toxic eﬀects on some organs such as liver, kidney, testis,
and heart [18–20]. It has been reported that Mtx-induced
liver damage may occur by a high dose or by chronic
application of methotrexate [6, 7]. Methotrexate may lead to
liver hepatotoxicity, including steatosis, cholestasis, ﬁbrosis,
and cirrhosis [21]. The mechanisms of Mtx-hepatotoxicity
can be related to its accumulation inside the cells in a
polyglutamated form. This form causes decreasing folat
levels and hepatotoxicity [22]. The other way; it is well
known that oxidative stress plays a role in tissue damage
caused by methotrexate [6, 23].
In our study, methotrexate caused increasing in MDA
and MPO levels. MDA, a stable metabolite of the free
radical mediated lipid peroxidation cascade, is used widely
as a marker of oxidative stress and lipid layers destroy
[24]. As described above, methotrexate caused lipid per-
oxidations via a signiﬁcant increase in MDA levels. Lipid
peroxidation, mediated by oxygen-free radicals, is believed
to be an important cause of destruction and damage to cell
membranes and has been suggested to be a contributing
factor to the development of methotrexate-mediated tissue
damage [25]. Similarly, there were many studies about
methotrexate-induced lipid peroxidations in liver tissue of
rats though elevated MDA levels and these ﬁndings are
in agreement with our results [3, 26, 27]. We and other
reserchers thought that these eﬀects of methotrexate may be
due to its binding lipids in cell membrane [3, 28]. Also, it has
determined that methotrexate leads to histological damage
including eosinophilic-stained and swollen hepatocytes. The
histological alterations may occur though methotrexate
oxidative properties. These results are conﬁrmed with other
previous studies. In the current study, also MPO activ-
ity which is an index of inﬂammation increased in the
methotrexate-treated group. Free radicals seem to trigger
the accumulation of leukocytes in the tissues involved and
thus aggravate tissue injury indirectly through activated
neutrophils. It has been shown that activated neutrophils









Figure 3: (a)Notice decreased glycogen storage inhepatocytes of Mtx+ MLgroup. (b)Viewof glycogen storagein hepatocytes in ML+ Mtx
group. (c) The appearance of the swollen hepatocyte in Mtx + ML group (arrows). (d) Eosinophilic-stained hepatocytes are still observed
(arrows) in ML + Mtx group. X66.
Table 2: Comparison of the eﬀect of ML on microscopic damage caused by Mtx in liver.
Parameters Control ML Mtx Mtx + ML ML + Mtx
Microscopicdamage 0.3 ± 0.5 0.8 ± 0.9 4.7 ± 0.9a 3.3 ± 0.5b,c 3.2 ± 0.7b
aSigniﬁcantly increased when compared with control group, P = 0.001.
bSigniﬁcantly decreased when compared with Mtx group, P = 0.005 and P = 0.01.
cNo signiﬁcance when compared with ML + Mtx, P = 0.8.
liberate oxygen radicals [29]. MPO, a member of the
haem peroxidase-cyclooxygenase superfamily, is abundantly
expressed in neutrophils and to a lesser extent in monocytes
and certain type of macrophages. MPO plays a fundamental
role in superoxide production [30]. The oxidative stress is
an imbalance between lipid peroxdations and antioxidative
system including GSH, a radical scavenger [31, 32]. In our
study, there was no diﬀerence in GSH levels. One possible
explanation of this ﬁnding was that GSH levels increased in
chronic injury. Ozbek et al. [33] reported that GSH levels
increased in chronic injury, whereas SOD and CAT enzyme
activities are elevated in the acute phase of damage. We only
give methotrexate to rats for one day, so GSH levels were not
aﬀected.
Montelukast, one of the selective reversible CysLT1
receptor antagonist, is used for the maintenance treat-
ment of asthma and to relieve symptoms of seasonal
allergies [34]. It is reported that montelukast can reduce
eosinophilic inﬂammation in the airways [35–37]. Besides
CysLT1 receptor antagonists or biosynthesis inhibitors ame-
liorate at ethanol-induced gastric mucosal damage [38]
and wound healing [39, 40]. According to our results,
montelukast treatment after Mtx injection reduced the MDA
and MPO levels. This can be attributed to its antioxidant
and anti-inﬂammatory capacity. In recent studies, it has
been shown that montelukast has antioxidant eﬀect [10–12].
Coskun et al. [41]a n dC u c i u r e a n ue ta l .[ 8]r e p o r t e d
that montelukast could reduce MDA and MPO levels as
antioxidant. Our biochemical results suggested that mon-
telukast treatment before methotrexate injection did not
aﬀect methotrexate-induced damage. However, in histolog-
ical ﬁndings, treatment with montelukast after methotrexate
injection and treatment with montelukast before methotrex-
ate injection were similar in term of histological score. In
addition, ML + Mtx group showed eosinophilic-stained
hepatocytes. It is known that eosinophilic-stained cellsThe Scientiﬁc World Journal 5
show the starting irreversible damage in the tissue. On the
other hand, there were degenerative changes as swelling of
hepatocytes (reversble damage) in the Mtx + ML group.
Whereas the histological scores of Mtx + ML and ML + Mtx
groupsaresimilar,Mtx+MLgroupshowedreversbldamage.
Beside its antioxidant and anti-inﬂammatory eﬀect,
montelukast has other mechanisms of action through its
decrease the severity hepatopathy. It is possible that mon-
telukast could inhibit the chloride conductance in hepato-
cytes. It is also known that LTD4,am e m b e ro fL T s ,a c t i v a t e s
a chloride conductance in hepatocytes, and ion channel
activation is associated with cytotoxicity [42].
5. Conclusion
The present study demonstrates that montelukast treatment
after methotrexate injection reduces the oxidative damage in
the liver tissue. These therapeutic eﬀects can be attributed to
its action on oxidant-antioxidant systems and inﬂammation
process. Although, further experimental and clinical studies
are required to conﬁrm these ﬁndings before its clinical
applications against liver injury.
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